Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:MSON's Cash-to-Debt is ranked higher than
100% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 1.84 vs. NAS:MSON: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:MSON' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22  Med: 5.7 Max: No Debt
Current: No Debt
Equity-to-Asset 0.88
NAS:MSON's Equity-to-Asset is ranked higher than
93% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. NAS:MSON: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:MSON' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.74 Max: 0.9
Current: 0.88
0.5
0.9
Interest Coverage No Debt
NAS:MSON's Interest Coverage is ranked higher than
99% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 83.04 vs. NAS:MSON: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:MSON' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 16.92
Beneish M-Score: -3.24
WACC vs ROIC
3.88%
-56.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -25.22
NAS:MSON's Operating Margin % is ranked lower than
72% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. NAS:MSON: -25.22 )
Ranked among companies with meaningful Operating Margin % only.
NAS:MSON' s Operating Margin % Range Over the Past 10 Years
Min: -35.87  Med: -18.51 Max: -4.22
Current: -25.22
-35.87
-4.22
Net Margin % -5.07
NAS:MSON's Net Margin % is ranked lower than
64% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. NAS:MSON: -5.07 )
Ranked among companies with meaningful Net Margin % only.
NAS:MSON' s Net Margin % Range Over the Past 10 Years
Min: -28.56  Med: -4.13 Max: 25.09
Current: -5.07
-28.56
25.09
ROE % -4.84
NAS:MSON's ROE % is ranked lower than
64% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: 3.48 vs. NAS:MSON: -4.84 )
Ranked among companies with meaningful ROE % only.
NAS:MSON' s ROE % Range Over the Past 10 Years
Min: -21.42  Med: -5.53 Max: 27.78
Current: -4.84
-21.42
27.78
ROA % -4.34
NAS:MSON's ROA % is ranked lower than
61% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 0.81 vs. NAS:MSON: -4.34 )
Ranked among companies with meaningful ROA % only.
NAS:MSON' s ROA % Range Over the Past 10 Years
Min: -18.21  Med: -4.01 Max: 24.23
Current: -4.34
-18.21
24.23
ROC (Joel Greenblatt) % -57.27
NAS:MSON's ROC (Joel Greenblatt) % is ranked lower than
69% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 7.00 vs. NAS:MSON: -57.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:MSON' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -57.86  Med: -31.07 Max: -7.66
Current: -57.27
-57.86
-7.66
3-Year Revenue Growth Rate 12.20
NAS:MSON's 3-Year Revenue Growth Rate is ranked higher than
75% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. NAS:MSON: 12.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:MSON' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.3  Med: 5.9 Max: 36.3
Current: 12.2
-35.3
36.3
3-Year EBITDA Growth Rate 21.00
NAS:MSON's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. NAS:MSON: 21.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:MSON' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.9  Med: -18.7 Max: 37.8
Current: 21
-55.9
37.8
3-Year EPS without NRI Growth Rate -24.80
NAS:MSON's 3-Year EPS without NRI Growth Rate is ranked lower than
82% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. NAS:MSON: -24.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:MSON' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.6  Med: -17.35 Max: 169.2
Current: -24.8
-53.6
169.2
GuruFocus has detected 2 Warning Signs with Misonix Inc $NAS:MSON.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MSON's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-05-05)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MSON Guru Trades in Q1 2016

Jim Simons 166,000 sh (+2.09%)
» More
Q2 2016

MSON Guru Trades in Q2 2016

Jim Simons 171,000 sh (+3.01%)
» More
Q3 2016

MSON Guru Trades in Q3 2016

Jim Simons 173,500 sh (+1.46%)
» More
Q4 2016

MSON Guru Trades in Q4 2016

Jim Simons 168,900 sh (-2.65%)
» More
» Details

Insider Trades

Latest Guru Trades with MSON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NAS:EDAP, NAS:DRAD, NAS:NVCN, OTCPK:TITXF, NAS:FONR, NAS:SPAN, OTCPK:AVMXF, NAS:VIVE, NAS:CGNT, OTCPK:BTCY, NAS:MGCD, NAS:ACRX, AMEX:ELMD, OTCPK:PHMZF, NAS:RWLK, OTCPK:RMSL, OTCPK:DIZTF, OTCPK:VICA, NAS:KOOL, OTCPK:TLTFF » details
Traded in other countries:MX9.Germany,
Misonix Inc designs, manufactures, markets and develops minimally invasive ultrasonic surgical device products. Its products include the BoneScalpel surgical system, the SonaStar Surgical Aspirator and the SonicOne Wound Cleansing and Debridement System.

Misonix Inc a New York corporation organized in 1959. The Company designs, manufactures, markets and develops minimally invasive ultrasonic medical device products. These products include the BoneScalpel cutting system which is used among other things for surgical procedures of the spine and on Maxillofacial procedures, the SonaStar Surgical Aspirator which is used to emulsify and remove soft and hard tumors, the SonicOne Wound Cleansing and Debridement System which offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells and the AutoSonix ultrasound cutting and coagulating system which is distributed and marketed for Misonix through Mentor Corporation, a subsidiary of Johnson & Johnson. The Company applications include the ability to transect or shape bone, ablate and aspirate both soft and hard tissue, cleanse and debridewounds and remove unwanted body fat. Among clinical specialties served are: Spine Surgery, Skull-Based Surgery (i.e., Cranio-Maxillo-Facial, Neurosurgery, Orthopedic Surgery and Plastic surgery). The Company sells its SonicOne Wound Cleansing and Debridement System, through direct sales persons and sales agents or distributors. The Companys main competitors are Johnson & Johnson, Valley Lab, a division of Tyco Healthcare, Integra Life Sciences, Inc., Sööring, and Stryker. The Companys medical device products are subject to the regulatory requirements of the U.S. Food and Drug Administration.

Top Ranked Articles about Misonix Inc

Interim CEO Invests in Misonix Insider acquires 761,469 shares
Stavros Vizirgianakis (Insider Trades), interim CEO and 10% owner of Misonix Inc. (MSON), acquired 761,469 shares in the company on Oct. 25. The price per share was $5.25 for a total transaction of $3,997,712. Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.30
MSON's PB Ratio is ranked lower than
51% of the 250 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. MSON: 3.30 )
Ranked among companies with meaningful PB Ratio only.
MSON' s PB Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.55 Max: 5.84
Current: 3.3
0.26
5.84
PS Ratio 3.50
MSON's PS Ratio is ranked lower than
52% of the 252 Companies
in the Global Medical Devices industry.

( Industry Median: 3.24 vs. MSON: 3.50 )
Ranked among companies with meaningful PS Ratio only.
MSON' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.26 Max: 5.53
Current: 3.5
0.12
5.53
Current Ratio 5.86
MSON's Current Ratio is ranked higher than
89% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. MSON: 5.86 )
Ranked among companies with meaningful Current Ratio only.
MSON' s Current Ratio Range Over the Past 10 Years
Min: 1.55  Med: 3.94 Max: 8
Current: 5.86
1.55
8
Quick Ratio 4.09
MSON's Quick Ratio is ranked higher than
83% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. MSON: 4.09 )
Ranked among companies with meaningful Quick Ratio only.
MSON' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 2.89 Max: 6.69
Current: 4.09
0.76
6.69
Days Inventory 251.80
MSON's Days Inventory is ranked lower than
79% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 125.61 vs. MSON: 251.80 )
Ranked among companies with meaningful Days Inventory only.
MSON' s Days Inventory Range Over the Past 10 Years
Min: 170.08  Med: 209.37 Max: 397.65
Current: 251.8
170.08
397.65
Days Sales Outstanding 61.10
MSON's Days Sales Outstanding is ranked higher than
61% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. MSON: 61.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
MSON' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.1  Med: 69.65 Max: 94.8
Current: 61.1
61.1
94.8
Days Payable 67.27
MSON's Days Payable is ranked higher than
56% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. MSON: 67.27 )
Ranked among companies with meaningful Days Payable only.
MSON' s Days Payable Range Over the Past 10 Years
Min: 33.6  Med: 74.13 Max: 108.56
Current: 67.27
33.6
108.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.90
MSON's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. MSON: -2.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MSON' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4  Med: -1.2 Max: 11.4
Current: -2.9
-4
11.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.11
MSON's Price-to-Net-Cash is ranked higher than
65% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 19.91 vs. MSON: 14.11 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MSON' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.06  Med: 9.03 Max: 86.83
Current: 14.11
2.06
86.83
Price-to-Net-Current-Asset-Value 5.05
MSON's Price-to-Net-Current-Asset-Value is ranked higher than
68% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 6.90 vs. MSON: 5.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MSON' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.09  Med: 3.29 Max: 5.16
Current: 5.05
1.09
5.16
Price-to-Tangible-Book 3.68
MSON's Price-to-Tangible-Book is ranked higher than
53% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 4.05 vs. MSON: 3.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MSON' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.75  Med: 2.08 Max: 3.68
Current: 3.68
0.75
3.68
Price-to-Intrinsic-Value-Projected-FCF 7.20
MSON's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
82% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. MSON: 7.20 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MSON' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.09  Med: 2.17 Max: 9.22
Current: 7.2
1.09
9.22
Price-to-Median-PS-Value 2.78
MSON's Price-to-Median-PS-Value is ranked lower than
92% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. MSON: 2.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MSON' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.08 Max: 2.78
Current: 2.78
0.38
2.78
Earnings Yield (Greenblatt) % -6.95
MSON's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. MSON: -6.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MSON' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.88  Med: 0 Max: 83.3
Current: -6.95
-7.88
83.3

More Statistics

Revenue (TTM) (Mil) $23.11
EPS (TTM) $ -0.16
Beta0.20
Short Percentage of Float0.66%
52-Week Range $3.83 - 11.50
Shares Outstanding (Mil)9.01
» More Articles for MSON

Headlines

Articles On GuruFocus.com
Insiders Sell MasterCard, Microsoft Oct 28 2016 
Interim CEO Invests in Misonix Oct 27 2016 
Weekly CFO Buys Highlight May 19 2013 
MISONIX Inc. (MSON) CEO Michael A Jr Mcmanus buys 5,000 Shares Dec 01 2009 
MISONIX Inc. Reports Operating Results (10-Q) Nov 16 2009 
MISONIX Inc. Reports Operating Results (10-K) Sep 28 2009 
MISONIX Inc. Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... Feb 17 2017
MISONIX INC Financials Feb 15 2017
MISONIX INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Feb 13 2017
Misonix Reports Receipt of Deficiency Letter from The Nasdaq Stock Market LLC Feb 13 2017
MISONIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Feb 10 2017
Misonix reports 4Q loss Feb 09 2017
Misonix reports 4Q loss Feb 09 2017
Misonix Files Form 10-K Announcing Fiscal 2016 Financial Results Feb 09 2017
MISONIX INC Files SEC form 10-K, Annual Report Feb 09 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... Jan 04 2017
MISONIX INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Dec 19 2016
Stavros G. Vizirgianakis Appointed President and CEO of Misonix, Inc. Dec 19 2016
Stavros G. Vizirgianakis Appointed President and CEO of Misonix, Inc. Dec 19 2016
MISONIX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 28 2016
Misonix Reports Nasdaq's Acceptance of Its Plan to Regain Listing Compliance Nov 28 2016
DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Misonix, Inc. and... Nov 17 2016
Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming November 18th... Nov 17 2016
FRIDAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Misonix, Inc.... Nov 16 2016
GPM Reminds Investors of the November 18th Deadline in the Class Action Lawsuit Against Misonix,... Nov 16 2016
MISONIX INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Nov 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)